Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2025)

Anaptysbio's Other Accumulated Expenses history spans 8 years, with the latest figure at $16.4 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 45.71% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $16.4 million, down 45.71%, while the annual FY2025 figure was $16.4 million, 45.71% down from the prior year.
  • Other Accumulated Expenses reached $16.4 million in Q4 2025 per ANAB's latest filing, down from $30.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $30.2 million in Q4 2024 to a low of $197000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 3 years is $15.6 million, with a median of $16.4 million recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 78.06% in 2021, then plummeted 45.71% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $197000.0 in 2021, then skyrocketed by 15236.55% to $30.2 million in 2024, then tumbled by 45.71% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Other Accumulated Expenses are $16.4 million (Q4 2025), $30.2 million (Q4 2024), and $197000.0 (Q1 2021).